Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement



#### PURAPHARM CORPORATION LIMITED

### 培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1498)

## CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

The Board announces that with effect from 1st February 2018:

- (i) Mr. Cheng Hok Kai, Frederick has resigned as the company secretary and authorised representative of the Company as required under the Listing Rules and the Companies Ordinance;
- (ii) Mr. Lau Ka Kuen has been appointed as the company secretary of the Company and one of the authorised representatives of the Company as required under Rule 3.05 of the Listing Rules and the authorised representative of the Company as required under the Companies Ordinance and Rule 19.05(2) of the Listing Rules.

# RESIGNATION OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE OF THE COMPANY AS REQUIRED UNDER THE LISTING RULES AND COMPANIES ORDINANCE

The board (the "Board") of directors (the "Directors") of PuraPharm Corporation Limited (the "Company" and together with its subsidiaries referred to as the "Group") announces that Mr. Cheng Hok Kai, Frederick ("Mr. Cheng") has resigned as (i) the company secretary; (ii) one of the authorised representatives as required under Rule 3.05 of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange"); and (iii) the authorised representative for accepting service of process and notices on behalf of the Company as required under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Companies Ordinance") and Rule 19.05(2) of the Listing Rules, of the Company with effect from 1st February 2018 due to his wishes to devote more time on his personal endeavours.

Mr. Cheng has confirmed that there is no disagreement with the Board and that there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Cheng for his contribution to the Company during the tenure of his service.

## APPOINTMENT OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE OF THE COMPANY AS REQUIRED UNDER THE LISTING RULES AND COMPANIES ORDINANCE

Following Mr. Cheng's resignation as company secretary and authorised representative of the Company as required under the Listing Rules and Companies Ordinance, Mr. Lau Ka Kuen ("Mr. Lau") has been appointed as the company secretary of the Company with effect from 1st February 2018.

Mr. Lau joined the Group in 2013 and is currently the Group financial controller of the Company. He is responsible for the day-to-day operations of the finance and accounting department. Prior to joining the Group, Mr. Lau was the staff accountant, associate, senior auditor and later on an audit manager in Deloitte Touche Tohmatsu, Hong Kong, a certified public accounting firm in Hong Kong, where he was primarily responsible for audit of companies listed on the Stock Exchange. Mr. Lau was accredited as a chartered public accountant by the Hong Kong Institute of Public Accountants and a chartered financial analyst by the Chartered Financial Analyst Institute. He obtained a bachelor's degree in business administration in finance and information system from the Hong Kong University of Science and Technology.

In addition to the above, Mr. Lau has also been appointed as one of the authorised representatives of the Company as required under Rule 3.05 of the Listing Rules and the authorised representative of the Company for accepting service of process and notices on behalf of the Company in Hong Kong as required under Part 16 of the Companies Ordinance and Rule 19.05(2) of the Listing Rules with effect from 1st February 2018.

The Board would like to take this opportunity to welcome Mr. Lau in taking up his new roles in the Company.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 24 January 2018

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie, Mr. Chan Lung Sang and Ms. Man Yee Wai, Viola; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.